4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Heart failure (HF) is a chronic debilitating and potentially life-threatening condition. HF patients are usually at high risk of polypharmacy and consequently, potentially inappropriate prescribing leading to poor clinical outcomes. Based on the published literature, a comprehensive HF-specific prescribing review tool is compiled to avoid medications that may cause HF or harm HF patients and to optimize the prescribing practice of HF guideline-directed medical therapies. Recommendations are made in line with the last versions of European Society of Cardiology (ESC) guidelines, ESC position papers, scientific evidence, and experts’ opinions.

          Related collections

          Author and article information

          Contributors
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          Journal
          European Heart Journal - Cardiovascular Pharmacotherapy
          Oxford University Press (OUP)
          2055-6837
          2055-6845
          September 17 2020
          September 17 2020
          Affiliations
          [1 ]Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, New Cairo, Egypt
          [2 ]Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy
          [3 ]Department of Pharmacology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERCV, Madrid, Spain
          [4 ]Department of Cardiology, Oslo University Hospital, Oslo, Norway
          [5 ]Department of Cardiology, Institute of Clinical Sciences, University of Oslo, Oslo, Norway
          [6 ]Department of of Internal Medicine and Cardiology, VIVIT Institute, Landeskrankenhaus Feldkirch, Feldkirch, Austria
          [7 ]Department of Molecular and Clinical Sciences Research Institute, St George's, University of London, St Georges Hospital, Room 0.246D, Corridor 9, Ground Floor, Jenner Wing, London, UK
          [8 ]Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
          [9 ]Department of Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
          [10 ]Department of Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy
          [11 ]Department of Medicine, Karolinska Institutet and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
          Article
          10.1093/ehjcvp/pvaa108
          32941594
          bb06d7bc-6628-4c6f-866d-6c37688748ad
          © 2020

          https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

          History

          Comments

          Comment on this article